FBW7 deficiency (including loss, low expression and mutation) leads to upregulation of MCL1 protein, resulting in irinotecan/SN38 resistance in CRC; inhibition of MCL1 by Maritoclax enhanced the antitumor efficacy of irinotecan/SN38. This evidence concerns the gene FBXW7 and colorectal carcinoma.